title: L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis?
authors.affiliation: Cleveland Clinic, Lerner College of Medicine, Center for Vasculitis Care and Research, Cleveland, United States. hoffmag@ccf.org
authors.forename: Gary S
authors.initials: GS
authors.lastname: Hoffman
mesh_terms: D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000188:drug therapy*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D003299:Cooperative Behavior; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D033183:Interdisciplinary Communication; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000592:standards; D012074:Remission Induction; D000069283:Rituximab; D055502:Secondary Prevention; D059039:Standard of Care / Q000592:standards*; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D000069283:Rituximab; D003520:Cyclophosphamide; D009173:Mycophenolic Acid; D001379:Azathioprine; D008727:Methotrexate